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Abstract 
Summary: We reviewed 371 consecutive patients from Oct. 2008 to Sept. 2011 who underwent 
posterior instrumented spinal arthrodesis and received intrawound vancomycin powder prior to 
closure and compared their acute, deep infection rate to 371 consecutive patients from Oct. 2008 
to Apr. 2005 who underwent posterior spinal instrumented arthrodesis and did not receive 
intrawound vancomycin. We found the use of vancomycin powder decreased the acute, deep 
Staphylococcus infection rate from 2.05% to 0 (p=0.008). Vancomycin powder is an effective 
way to decrease acute, deep S. aureus infections following spine surgery. 
Introduction: Surgical site infection is a serious complication for patients undergoing 
instrumented spinal surgery.  Staphylococcus aureus is the most common causative agent 
associated with post-op wound infections. Recent studies have reported a decreased infection 
rate with intrawound vancomycin use in spine surgeries. We sought to determine if intrawound 
vancomycin would decrease the rates of acute, deep S. aureus infections in our posterior 
instrumented spinal arthrodesis patients. 
Methods: This is a historical cohort study. All procedures were performed by a single surgeon. 
371 consecutive patients undergoing posterior instrumented spinal arthrodesis received 
intrawound vancomycin in addition to standard antimicrobial prophylaxis beginning in Oct. 2008 
through Sept. 2011 (Vanco cohort).  We compared them to 371 consecutive patients from Oct. 
2008 to Apr. 2005 who did not receive intrawound vancomyin (Historical cohort). We excluded 
any superficial infection (above the lumbosacral fascia) or any infection occurring after 90 days.  
Infection rates were analyzed with Fisher exact test. 
Results: We found 8 (2.4%) acute, deep infections in the Historical cohort: 1 Enterococcus and 
7 (2.05%) Staphylococcus (6 of which were S. aureus). We found 4 (1.2%) acute, deep infections 
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in the Vanco group, none of which were S. aureus. There were 2 E.coli, 1 Klebsiella oxytoca, 
and 1 anaerobic Streptococcus. The difference in total acute, deep infection rate between the 
Historical cohort and Vanco cohort was not significant (p= 0.262), but the decrease in 
Staphylococcus infection rate in the Vanco group was significant (p=0.008).  
Conclusion: Intrawound vancomycin powder has decreased the rate of acute, deep 
Staphylococcus infections in our posterior instrumented spinal fusion patient population from 
2.05% to 0. Our Vanco cohort was significantly older but otherwise similar in terms of risk 
factors to the Historical cohort, though had fewer infections.  This work is adding to the growing 
body of evidence in support of this effective adjuvant to standard antimicrobial prophylaxis. 
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Background 
 Incidence and cost of surgical site infections  
Surgical site infections (SSIs) are a common concern among the surgical specialties.  
They dramatically increase the cost associated with the surgical procedure and negatively affect 
patient outcomes. There are approximately 500,000 SSIs annually in the United States1. Klevens 
et al, using 2002 data from the National Nosocomial Infections Surveillance System, National 
Hospital Discharge Survey, and American Hospital Association reported that 20% of the 1.7 
million hospital acquired infections were SSIs2. They found that approximately 2% of all 
operations result in a SSI2. Surgical site infections have been reported to increase the patient’s 
hospital stay by nearly ten days3, and SSIs are associated with increased mortality risk and 
financial costs4. Indeed approximately 77% of deaths in those patients with a SSI are attributed 
to the infection5, and nationally the total annual cost of SSIs is estimated to be between $1 billion 
and $10 billion6,7. 
Similar findings have been reported pertaining to orthopedic procedures specifically. 
Sampling the Agency of Healthcare Research and Quality (AHRQ) Healthcare Cost and 
Utilization Project dataset from 2005, de Lissovoy et al used a conservative approach and 
targeted a single SSI ICD9-CM code3. They found that compared to non-SSI controls, a single 
orthopedic SSI increased the length of the hospital stay by an average of 9.5 days and added an 
average additional $15,129 to the cost3. The incidence of surgical site infections in spinal 
surgeries has been reported nationally to be approximately 1.2% for laminectomies and 2.4% for 
arthrodeses8. Surgical site infection rates vary at individual centers depending on surgery type9.  
The most common cause of an orthopedic SSI is Staphylococcus aureus followed by 
coagulase-negative staphylococci 6,10. These gram-positive cocci from the patient’s own skin 
flora are the leading source of bacterial inoculums6,11. Noskin et al, using the AHRQ Nationwide 
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Inpatient Sample conducted a retrospective analysis of hospital stays for 200312. Specifically 
targeting ICD9-CM codes for S. aureus, they reported that inpatient stays involving orthopedic 
surgery had S. aureus infection rate of 1.8%. The additional mortality risk and cost associated 
with such an infection was 2.5% and $34,202 respectively. From 1998 to 2003 there was a 53% 
increase in the prevalence of S. aureus infections in orthopedic surgery12. Total annual economic 
burden of S. aureus SSIs for inpatient orthopedic surgery was estimated to be $1.5 billion in 
200312.  
Unfortunately, methicillin-resistant Staphylococcus aureus (MRSA) SSIs have recently 
been shown to have worse health outcomes and higher health service costs compared to 
methicillin-sensitive Staphylococcus aureus (MSSA). In a multi-center matched-outcomes study, 
Anderson et al13 compared cardiothoracic, neurosurgical, and orthopedic surgery patients with a 
MRSA SSI to those with a MSSA SSI or no SSI from 1998 to 2003. They assessed hospital 
readmissions, mortality, total hospital days, and hospital charges (inflated to 2003 dollars) 
associated with MRSA SSIs compared to uninfected matched controls and to unmatched MSSA 
controls. They reported patients with a MRSA SSI were 30 times more likely to have a hospital 
readmission, and seven times more likely to die within the 90 days post-operative period 
compared to those patients without an SSI13. These MRSA SSI patients had more than $60,000 
of additional hospital charges, and had 16 more days hospitalized compared to uninfected 
patients. Compared to MSSA SSI, a MRSA SSI was associated with an additional six days of 
hospitalization and more than $23,000 of additional hospital charges. They report that preventing 
a single SSI caused by MRSA can save hospitals $61,00013. A similar increase in mortality risk 
associated with MRSA bacteremia compared to MSSA was observed in a 2003 meta-analysis by 
Cosgrove et al14. 
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Risk factors for surgical site infections in spinal surgery 
As a result of the significant costs associated with SSIs and specifically those caused by 
MRSA, infection prevention is a very attractive area of research. Prevention efforts have been 
two fold; 1) identify and reduce the risk factors associated with SSI and 2) develop prophylactic 
antimicrobial treatments for SSI. Risk factors for SSI can be classified as preoperative factors, 
operative factors, and postoperative factors.  
Preoperative risk factors for SSI after spinal surgery include history of inflammatory 
arthritis15, diabetes15,16, past SSIs15, cigarette smoking17, immunosuppressant drug use16, 
obesity16, serum glucose greater than 125 mg/dL18, preoperative shaving with a razor5, and nasal 
colonization with S. aureus19. Operative risk factors for SSI after spinal surgery include extended 
length of surgery15,16,20, estimated blood loss (EBL) greater than one liter15,16, a posterior surgical 
approach15,21, instrumentation22, sub-optimal timing of prophylactic antibiotics18, two or more 
residents participating in the surgery18,  poor homeostasis5, and surgical case order23. Blood 
transfusions have been associated with SSIs, but not necessarily linked as a risk factor20. 
Postoperative risk factors include long duration of immobility16, use of total-contact braces16, and 
serum glucose greater than 200 mg/dL18. 
The CDC released a guideline for recommended SSI preventative measures in 19995. 
According to the guidelines, risk factors that can be modified to prevent SSI include glucose 
control5,10,24, diabetes management5,10,16, smoking cessation5,10,16, pre-op treatment for unrelated 
infections (e.g. UTIs) 10,16,  proper hair removal (clippers or depilatory, not razors) 5,10,16, 
minimizing operating room traffic flow5,16, and proper operative aseptic technique5,16.   
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Current antimicrobial prophylaxis for surgical site infections 
Antimicrobial prophylaxis (AMP) is currently recommended for high risk orthopedic 
surgery, including spinal instrumentation, where infection could result in catastrophic 
outcomes5,16. Standard AMP for spinal orthopedic surgery at Kansas University Medical Center 
includes 20 mg/kg body weight of Ancef given intravenously within one hour prior to incision 
and with repeat dosing every four hours during surgery. Post-operatively, patients are given 1 g 
of Ancef intravenously every eight hours for 24 hours. If the patient is a known MRSA carrier or 
is allergic to Ancef, 1 g of vancomycin given intravenously can be substituted, as has been done 
in previous studies10,16,24-27. Additionally, all patients are given chlorhexidine towels and 
instructed to wash with them the night before and the morning of surgery. The operative location 
is prepped with alcohol, betadine wash and betadine paint prior to incision. 
Risk factor reduction protocols and proper AMP therapy are generally part of the surgical 
standard of care at most facilities. However, maintaining these preventive measures has not 
resulted in a reduction in SSI incidence in the past decade, and refinement of these techniques is 
unlikely to cause a significant decrease20. Finding new antimicrobial prophylactic treatments for 
SSIs is now imperative for protecting our patients’ quality of life post-operatively and for 
controlling health care costs. 
New methods for antimicrobial prophylaxis 
The main AMP techniques being researched and reported on include preoperative 
bacteria decolonization with chlorhexidine baths10,16, routine screening and eradication of 
intranasal MRSA/MSSA flora10,16, and topical application of vancomycin powder to the surgical 
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wound before closure25,27,28. Additional AMP benefit has been demonstrated with soaking the 
wound with dilute-betadine for three minutes prior to wound closure29. 
 Bathing with chlorhexidine products is not currently recommended for SSI 
prevention10,16. Although chlorhexidine baths, with simultaneous intranasal bacterial eradication 
with mupirocin, have recently been shown to be effective in preventing SSIs in elective total 
joint arthroplasty30, they have not been shown to be efficacious alone31. If chlorhexidine baths 
are proven effective, computer models have predicted that this will be a cost effective method to 
prevent SSIs32.   
Universal screening and eradication of intranasal S. aureus with mupirocin is not 
currently recommended for SSI prevention10,16. It was not shown to decrease the rate of SSIs33,34. 
However, it was shown to decrease the rate of SSIs in people colonized with S. aureus33. 
Intranasal bacterial eradication with mupirocin has also been shown to be effective in specific 
surgical populations, like orthopedics35. Both chlorhexidine baths and intranasal mupirocin are 
limited to elective surgery and require patient compliance. Resistance to mupirocin therapy has 
been demonstrated, which casts doubt on this treaments long-term efficacy potential6,36. 
Routine use of intravenous vancomycin for SSI prophylaxis is not recommended10,24. It 
has not been shown to be any more effective than using intravenous cephalosporins (e.g. Ancef) 
in preventing SSIs37, nor has it been shown to be any more effective in preventing MRSA SSIs38. 
Recently, administering vancomycin powder locally, directly to the wound, has been shown to 
decrease SSI rates following spinal surgery procedures20,22,24, and this has been shown effective 
in emergent settings, such as trauma, where pre-operative decolonization would not be 
possible22. This intrawound vancomycin powder AMP appears to have the greatest potentional to 
prevent SSIs in spinal surgery. However, only one of these studies was in a diverse spinal 
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surgery population20, and more studies are needed to confirm the efficacy of intrawound 
vancomycin powder to prevent surgical site infections in spinal surgeries.  
Study purpose 
Given the high costs associated with surgical site infections in terms of mortality risk and 
health services costs and because SSI rates are not decreasing even with increased surveillance 
and standard AMP measures, new prophylactic measures need to be developed. Of those 
prophylactic measures currently reported, intrawound vancomycin powder appears to be the 
most successful at preventing surgical site infections in posterior instrumented spinal surgeries. 
The purpose of this study was to determine if the use of intrawound vancomycin powder has 
decreased the rate of acute surgical site infections in posterior instrumented spinal arthrodesis 
surgeries at the University of Kansas Medical Center.  
Methods 
 Study design 
This was a historical cohort study design and was approved by the Human Subjects 
Committee of the University of Kansas Medical Center. A single surgeon at the University of 
Kansas Medical Center performed all procedures. Beginning October of 2008 all patients 
undergoing posterior instrumented spinal arthrodesis received between 0.5 g to 2 g of 
vancomycin powder applied directly to the wound just prior to closure, in addition to standard 
AMP. The vancomycin powder dose was based on wound size at the discretion of the surgeon. 
There were 690 consecutive spinal surgeries performed between October 2008 and September 
2011 (Fig. 1). Of these 690 surgeries, 371 of them were posterior instrumented spinal 
arthrodeses, and these became our Vanco cohort. To identify our Historical control cohort, which 
did not receive intrawound vancomycin powder, we identified 371 consecutive posterior 
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instrumented arthrodesis surgeries immediately prior to October 2008. In order to find these 371 
surgeries, we examined 765 consecutive spinal surgeries from April 2005 to October of 2008. To 
be included in our analysis patients had to have a minimum of 90 days of follow-up or a SSI 
occurring within 90 days of operation. Figure 1 displays the breakdown of surgical procedures 
performed by year. 
 
Figure 1: Type of procedures performed by study group per year 
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Demographic and operative data were gathered for all patients; including, age, gender, 
race, BMI, primary insurance, American Society of Anesthesiologists (ASA) grade, prior history 
of SSI, current cigarette use, any alcohol use, illicit drug use, previous spinal surgeries at the 
same spinal level, length of hospitalization, discharge location, admitting diagnoses, blood 
transfusions, number of residents participating in surgery, estimated blood loss, length of 
surgery, number of levels instrumented and fused, use of  an associated anterior approach, a 
decompression or pelvic fixation, hair removal method, hemovac drain use, co-morbidities, 
intrawound vancomycin use and surgical site infections.  For a complete listing of variable 
definitions and chart locations see appendix A. 
 Identification of surgical site infections 
Acute SSI was our primary outcome. We defined an SSI as occurring within 90 days 
following the operation, requiring an additional operation (i.e. an irrigation and debridement) and 
having positive wound cultures. Infections were further subdivided into superficial (occurring 
above the lumbosacral fascia) or deep (beneath the lumbosacral fascia) based on the 
microbiology wound culture reports and operative reports.  For all patients having an SSI, the  
number of days post-op that the SSI was diagnosed, number of operations needed to treat the 
SSI, wound vacuum assisted closure use for the SSI, and number of additional days hospitalized 
were recorded.  
Statistical analysis  
Continuous data between the Vanco cohort and Historical control cohort were compared 
using the T-test and categorical data were compared using chi-square test or Fisher’s exact test. 
The rate of SSIs was compared between the Vanco cohort and the Historical control cohort using 
chi-square test. Similarly, we compared the rates of deep infections, deep Staphylococcus 
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infections and deep S. aureus infections between the two groups. If expected cell counts were 
five or fewer we used Fisher’s exact test.  
Univariate analysis was then used to compare those patients who had a SSI and those 
who did not. We identified those variables that were significantly associated with having any 
SSI, superficial or deep, (p<0.10) and those that were clinically relevant and fit a multiple 
variable logistic regression model. We then did a post-hoc power analysis to assess the power of 
this study to detect a significant decrease in total infections between our study groups.  Subjects 
with missing data points were excluded from analysis of that data. We used two-tailed tests for 
all analyses with a significance level set at p<0.05. All data analysis was performed with SAS 
9.3 (SAS Institute Inc., Cary, NC, USA).  
Results 
  We had 92% of the 371 cases with 90 days or greater follow-up in both study groups 
(N=342 for Vanco cohort and N=341 for Historical cohort).  One of the patients in the Historical 
cohort expired during the operative hospital stay due to a pulmonary embolism, some of the 
other patients were also deceased at the time of data abstraction but actual death dates were not 
documented. Most patients without the required 90 days of follow-up were listed in the records 
as having not kept their follow-up appointment, but without further explanation. Some of the rest 
of the patients were without follow-up unknown reasons. In the Vanco cohort a small number of 
the patients were not scheduled back for their follow-up until after the data abstraction period.  
So while they very well may have complete follow-up, we were not able to capture it.  
 The demographic and operative data are listed in Table 1 and Table 2 respectively. The 
Vanco cohort was significantly older with a mean age of 55.3 (standard deviation of 19.1 years) 
compared to the historical cohort with a mean age of 49.1 (standard deviation of 20.9 years) 
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(p<0.0001).  The Vanco cohort had a higher number of patients with hypertension at 56.7% of 
patients compared to 41.9% in the Historical cohort (p<0.0001).  Largely the demographic and 
hospital stay data were similar across the two study groups.  
Table 1: Comparison of Demographic and Hospitalization Characteristics for Patients Receiving and 
Not Receiving Intrawound Vancomycin 
Patient Characteristics 
Vanco Cohort 
(N= 342) 
Historical Cohort 
(N=341) 
T-test or Chi-
square 
Age, mean (SD) 55.3 (19.1) 49.1 (20.9) p<0.0001 
Gender (%) 
  
p=0.302 
Male 45.3 49.3   
Female 54.7 50.7   
Race (%) 
  
p=0.101 
Caucasian 85.7 87.7   
African-American 8.2 7.0   
Hispanic 1.8 3.5   
Other 4.39 1.76   
Adult Body Mass Index, mean (SD)¹  31.6 (7.3)  30.7 (7.0) p=0.130 
Adult BMI group (%)¹ 
  
p=0.048 
 Normal (≤25 kg/m2)  15.9 24.4   
 Overweight (>25 and <30 kg/m2) 31.1 24.4   
Obese (≥30 and ≤35 kg/m2) 25.6 25.4   
 Morbidly obese (>35 kg/m2) 27.5 25.8   
Co-morbidities (%) 
  
  
Diabetes² 18.1 15.0 p=0.279 
Cardiovascular Disease²  17.5 13.3 p=0.123 
Respiratory Disease² 17.5 14.5 p=0.272 
Hypertension² 56.7 41.9 p=0.0001 
Mean ASA Grade (SD)³ 2.6 (0.6) 2.5 (0.6) p=0.067 
History of Surgical Site Infection (%)⁴ 1.8 3.9 p=0.098 
Current Cigarette Use at Time of Surgery (%)⁴ 5.6 6.5 p=0.602 
Any Alcohol Use (%)⁴ 37.1 24.9 p<0.001 
Mean Number of Days Hospitalized Until 
Discharge or SSI (SD) 5.9 (4.5) 6.32 (4.3) p=0.350 
Insurance Type (%)² 
  
p=0.002 
Commercial 44.4 44.7   
Medicare 35.7 26.5   
Medicaid 5.9 13.5   
Workmen's Comp 14.0 15.3   
Discharge Location (%) 
  
p=0.077 
Home 83.3 88.3   
Inpatient Rehabilitation 10.8 9.1   
Skilled Nursing Facility 5.9 2.6   
¹Historical cohort N=283, Vanco cohort N=309, ²Historical cohort N=339, ³Historical cohort N=333, 
⁴Historical cohort N=338 
  
	  
	  
11	  
In the Vanco cohort 53.2% of the patients had a diagnosis of spinal stenosis compared to 
43.7% in the historical cohort, which was significantly larger (p=0.013), but the groups were 
similar in terms of other diagnoses. More of the patients in the Vanco cohort had had a previous 
surgery at the spinal level treated in this study (50.0%) compared to the Historical cohort 
(39.8%), and this was statistically significant (p=0.007). Almost all of the patients in the Vanco 
cohort had hair removal with electric clippers (98.8%) with the remainder having no hair 
removal (1.2%) and none of the patients had hair removed with a razor, however the historical 
cohort had 1.5% with razor hair removal, only 92.5% with electric clippers and the remaining 
6.0% had no hair removal. Differences among hair removal types were statistically significant 
(p<0.001). 
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Table 2: Comparison of Operative Characteristics for Patients Receiving and  
Not Receiving Intrawound Vancomycin 
Patient Characteristics 
Vanco Cohort 
(N= 342) 
Historical Cohort  
(N=341) 
T-test or Chi-
square 
Diagnosis (%)       
Spinal Stenosis 53.2 43.7 p=0.013 
Spondylolisthesis 39.5 44.9 p=0.154 
Degenerative Disc Disease/Herniated Disc 15.5 16.7 p=0.665 
Scoliosis 14.9 11.1 p=0.144 
Pseudoarthrosis 12.0 10.6 p=0.554 
Fracture 2.6 4.4 p=0.210 
Cancer 0.9 1.8 p=0.340 
Other 29.8 23.2 p=0.049 
Blood Transfusion (%)¹ 30.1 33.0 p=0.414 
Mean Number of Orthopedic Residents Involved 
in the Surgery  (SD) 
0.81 (0.43) 0.96 (0.38) p<0.0001 
Mean Estimated Blood Loss in mL (SD)² 635 (818) 616 (700) p=0.747 
Mean Length of Surgery in minutes (SD)³ 298 (125) 312 (129) p=0.158 
Mean Number of Levels Instrumented (SD) 3.8 (3.8) 3.6 (4.1) p=0.607 
Mean  Number of Levels Fused (SD) 3.3 (3.6) 3.3 (3.9) p=0.973 
Associated Anterior Approach (%)  20.2 23.8 p=0.259 
Decompression (%) 81.9 76.3 p=0.071 
Pelvic Fixation (%) 15.2 10.6 p=0.070 
Operative Levels (%)     p=0.237 
Cervical 7.0 5.6   
Thoracic 1.5 3.8   
Thoraco-lumbar 24.0 22.9   
Lumbar 67.5 67.7   
Previous Surgery (%)⁴ 50.0 39.8 p=0.007 
Hemovac Drain Used (%) 93.3 91.8 p=0.460 
Hair Removal  (%)⁵     p<0.001 
Clippers 98.8 92.5   
Razor 0.0 1.5   
None 1.2 6.0   
¹Historical cohort N=336, Vanco cohort N=341, ²Historical cohort N=332, Vanco cohort N=332, 
³Historical cohort N=334, Vanco cohort N=340, ⁴Historical cohort N=337, 
⁵Historical cohort N=333, Vanco cohort N=341 
 
 The rates of infection are listed in Table 3. We found an approximately 50% reduction in 
the rate of total infections in the Vanco cohort (2.1%) compared to the Historical cohort (4.4%), 
however this was not quite statistically significant (p=0.082). Similarly, there was a 50% 
reduction in deep infections in the Vanco cohort (1.2%) compared to the Historical cohort 
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(2.4%), and this was not statistically significant (p=0.262). None of the deep infections in the 
Vanco cohort cultured Staphylococcus from the wounds, whereas 7 of the deep infections in the 
Historical cohort did culture positive for MSSA, MRSA or coagulase-negative Staphylococcus, 
for a deep Staphylococcus infection rate of 2.1%. This decrease in deep Staphylococcus 
infections was statistically significant (p=0.008).  For a complete listing of bacteria cultured from 
the infections see appendix B. There were no adverse events associated with intrawound 
vancomycin powder use.   
Table 3: Comparison of Rates of Infections in Vanco and Historical Cohorts  
Infections 
Vanco Cohort 
(N= 342) 
Historical Cohort 
(N=341) 
Chi-square/Fisher 
Exact 
Any infection, number (%) 7 (2.1) 15 (4.4) p=0.082 
Deep infection, number (%) 4 (1.2) 8 (2.4) p=0.262 
Deep Staphylococcus1, number (%) 0 7 (2.05) p=0.008 
Deep S. aureus only, number (%) 0 6 (1.76) p=0.014 
1Includes S. aureus and S. epidermidis    
 
 When comparing those patients that had an infection (N=22) to those patients that did not 
have an infection (N=661), we found that those patients who developed a SSI had higher average 
ASA grades (2.9 compared to 2.5, p=0.007), a higher rate of blood transfusions (57.1% 
compared 30.8%, p=0.010), higher average length of surgery (366 minutes compared to 303 
minutes, p=0.024), higher rates of fracture diagnoses (18.2% compared to 3.0%, p=0.006), and a 
higher rate of having a past SSI (18.2% compared to 2.3%, p=0.002). Differences in 
demographic and operative characteristics between those patients developing a SSI and those not 
developing a SSI are listed in Tables 4 and 5 respectively. 
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Table 4: Comparison of Demographic and Hospitalization Characteristics for Patients With and Without 
Infection 
Patient Characteristics 
Non Infection  
(N= 661) 
Infection 
(N=22) 
T-test or Chi-
square 
Age, mean (SD) 52.3 (20.2) 48.8 (21.9) p=0.419 
Gender (%)     p=0.861 
Male 47.4 45.5 
 Female 52.7 54.6 
 Race (%)     p=0.723 
Caucasian 86.5 90.9 
 African-American 7.7 4.6 
 Hispanic 2.6 4.6 
 Other 3.18 0 
 Adult Body Mass Index, mean (SD)¹  31.2 (7.2) 31.6 (8.4) p=0.802 
Adult BMI group (%)¹     p=0.269 
 Normal (≤25 kg/m2)  19.7 27.8 
  Overweight (>25 and <30 kg/m2) 28.4 11.1 
 Obese (≥30 and ≤35 kg/m2) 25.6 22.2 
  Morbidly obese (>35 kg/m2) 26.3 38.9 
 Co-morbidities (%)     
 Diabetes² 16.2 27.3 p=0.237 
Cardiovascular Disease²  15.6 1.9 p=0.556 
Respiratory Disease² 16.1 13.6 p=1.000 
Hypertension² 54.6 49.2 p=0.620 
Mean ASA Grade (SD)³ 2.5 (0.6) 2.9 (0.5) p=0.007 
History of Surgical Site Infection (%)⁴ 2.3 18.2 p=0.002 
Current Cigarette Use at Time of Surgery (%)⁴ 6.1 4.6 p=1.000 
Alcohol Use (%)⁴ 31.5 18.2 p=0.244 
Mean Number of Days Hospitalized Until Discharge or 
SSI (SD) 6.0 (4.4) 7.7 (4.4) p=0.072 
Insurance Type (%)⁵     p=0.726 
Commercial 44.9 36.4 
 Medicare 30.9 36.4 
 Medicaid 9.6 13.6 
 Workmen’s Comp 14.7 13.6 
 Discharge Location (%)     p=0.083 
Home 86.1 77.3 
 Inpatient Rehabilitation 10.0 9.1   
Skilled Nursing Facility 3.9 13.6   
¹No infection group N=574, Infection group N=18, ²No infection group N=659 
³No infection group N=654, Infection group N=21, ⁴No infection group N=658 
⁵No infection group N=660 
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Table 5: Comparison of Operative Characteristics for Patients With and Without Infection 
Patient Characteristics 
Non Infection 
(N= 661) 
Infection 
(N=22) 
T-test or Chi-
square 
Diagnosis (%)    Spinal Stenosis 48.9 36.4 p=0.248 
Spondylolisthesis 42.4 36.4 p=0.575 
Degenerative Disc Disease/Herniated Disc 16.3 9.1 p=0.556 
Scoliosis 12.9 18.2 p=0.514 
Pseudoarthrosis 11.5 4.6 p=0.497 
Fracture 3.0 18.2 p=0.006 
Cancer 1.4 0.0 p=1.000 
Other 25.6 54.6 p=0.002 
Blood Transfusion (%)¹ 30.8 57.1 p=0.010 
Mean Number of Orthopedic Residents Involved in 
the Surgery (SD) 0.88 (0.4) 0.95 (0.2) p=0.153 
Mean Estimated Blood Loss in mL (SD)² 621 (764) 765 (674) p=0.394 
Mean Length of Surgery in minutes (SD)³ 303 (126) 366 (147) p=0.024 
Mean Number of Levels Instrumented (SD) 3.6 (3.9) 5.5 (5.7) p=0.134 
Mean  Number of Levels Fused (SD) 3.3 (3.7) 4.8 (5.2) p=0.195 
Associated Anterior Approach (%)  21.8 27.3 p=0.600 
Decompression (%) 79.3 72.7 p=0.431 
Pelvic Fixation (%) 12.1 36.4 p=0.004 
Operative Levels (%)   p=0.115 Cervical 6.4 4.6  Thoracic 2.7 0.0  Thoraco-lumbar 22.7 45.5  Lumbar 68.2 50.0  Previous Surgery (%)⁴ 44.6 54.6 p=0.356 
Hemovac Drain Used (%) 92.4 95.5 p=1.000 
Hair Removal  (%)³   p=0.111 Clippers 95.9 90.0  Razor 0.5 5.0  None 3.6 5.0  Intrawound Vancomycin Use (%) 50.7 31.8 p=0.082 
¹No infection group N=657, Infection group N=21, ²No infection group N=643, Infection group N=21 
³No infection group N=653, Infection group N=21, ⁴No infection group N=657 
 
In the multi-variable logistic regression model (N=673) we included intrawound 
vancomycin powder use, pelvic fixation, length of surgery, blood transfusion, diagnosis of 
fracture, discharge location, history of SSI, age and gender. Our model was significant 
(likelihood ratio chi-square = 35.2, p<0.001), and well fit (Hosmer-Lemeshow chi-square = 10.1, 
p=0.259). Regression results are displayed in Table 6. Intrawound vancomycin was negatively 
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associated with SSI (AOR= 0.479), however this was not significant (95% CI, 0.164-1.284; 
p=0.154). Operations that included a pelvic fixation (AOR= 4.194; 95% CI, 1.051-18.63; 
p=0.049), a diagnosis of fracture (AOR= 8.642; 95% CI, 1.865-35.81; p=0.004), an elevated 
ASA grade (AOR= 3.914; 95% CI, 1.324-13.975; p=0.021) or a discharge to a skilled nursing 
facility (AOR= 5.815; 95% CI, 1.084-25.666; p=0.025) had higher risk of developing a SSI.  
Table 6: Multi-variable Logistic Regression Analysis of Any Surgical Site Infection 
Variable 
Adjusted Odds Ratio 
Estimate 95% CI p-­‐value	  
Intrawound Vancomycin 0.479 0.164 1.284 0.154 
Pelvic Fixation 4.194 1.051 18.63 0.049 
Length of Surgery 1.001 0.996 1.005 0.662 
Blood Transfusion 0.515 0.122 1.998 0.349 
Diagnosis of Fracture 8.642 1.865 35.81 0.004 
Discharged to Inpatient Rehab 0.862 0.123 3.685 0.857 
Discharged to Skilled Nursing 
Facility 5.815 1.084 25.666 0.025 
History of Surgical Site Infection 4.244 0.718 19.145 0.077 
ASA Grade 3.914 1.324 13.975 0.021 
Model N=673, (21 with infections), Likelihood ratio chi-square= 35.2 (p<0.001), 	  	  
c-statistic= 0.804, and Hosmer-Lemeshow chi-square =10.1 (p=0.259) 	  	  
Model included all variables listed as well as age and gender 	  	  
ASA = American Society of Anesthesiologists 	  	  
 
 We used a power analysis for independent proportions to calculate the power of this 
study. Given a 4.4% rate of SSI for the Historical cohort and a 2.1% rate of SSI for the Vanco 
cohort, an alpha of 0.05 and 341 patients per group the power of our study was calculated to be 
39.5%. The number of patients needed to reach a power of 80% is 932 per group. We would 
have to add over 500 additional cases per study group achieve a power of 80%.  
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Discussion 
 The purpose of this study was to determine if the addition of intrawound vancomycin 
powder to the operative AMP regimen has decreased the rate of acute SSIs in our Vanco cohort 
compared to a Historical control cohort. We did not find a statistically significant decrease 
(p=0.082) in the rate of total SSIs in the Vanco cohort (2.1%) compared to our Historical cohort 
(4.4%), because our study was underpowered at 39.5% to do so. Even so, we found a near 50% 
reduction in infections between the two groups and with a 91.8% chance that this finding is not 
random, this is certainly clinically significant. 
  Although our study was underpowered and the sample size was relatively small 
compared to recent national studies which have identified risk factors for SSI in spinal surgeries, 
our multiple-variable regression analysis identified pelvic fixation (AOR 4.19; 95% CI, 1.05-
18.63), a fracture diagnosis (AOR 8.64; 95% CI, 1.87-35.81), discharge to a skilled nursing 
facility compared to being discharged home (AOR 5.82; 95% CI, 1.08-25.67) and ASA grade 
(AOR 3.91; 95% CI, 1.32-13.98) to be independent risk factors for developing a SSI. Length of 
surgery and having received a blood transfusion during or after the operation were included in 
the model but were not independently associated with increased infection risk after adjusting for 
the other variables. These two variables are likely inter-related with each other, as a longer 
surgery is likely to have greater blood loss which results in a blood transfusion.  
Pelvic fixation is similarly associated with increased length of surgery and also blood 
transfusion, yet remained an independent risk factor with a four times greater risk for SSI in the 
adjusted model. Perry et al analyzed 238 posterior instrumented arthrodesis surgeries and 
identified operations with pelvic fixation as being a risk factor for SSI and postulated that using 
pelvic fixations extends the incision closer to the anus which predisposes for gastrointestinal 
bacterial infections39. Of those eight patients with pelvic fixation that developed a SSI in our 
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study population, only three of them developed enteric related bacterial infections, which may 
not support the incision-anus-proximity theory. However, those patients with pelvic fixation and 
SSI did have complicated diagnoses (neuromuscular scoliosis, Duchenne’s muscular dystrophy, 
cerebral palsy, scoliosis, and fracture) and the severity of their diagnoses and the complexity of 
the operation to correct their deformities is likely responsible for their increased risk for SSIs.  A 
multi-center retrospective study of 210 patients undergoing spinal surgery for neuromuscular 
scoliosis identified allograft use and mental retardation as risk factors for infection, but did not 
include pelvic fixation in their analysis40.  
A diagnosis of fracture had an almost nine times higher risk of developing a SSI in our 
study. Our study included not only trauma fractures but also pathologic and osteoporotic 
fractures. Olsen et al identified fracture diagnosis as a risk factor for SSI in a univariate analysis 
of 2,316 patients undergoing laminectomy, discectomy and/or arthrodeses, but they did not 
report fracture as an independent risk factor in their multiple regression analysis18. Our findings 
are also supported by a case-series published by Rechtine et al that reported a SSI rate of 10% in 
112 patients with lumbar and thoracic fractures treated with instrumentation which was higher 
than national average rates26.  
The ASA grade is a measure of systemic disease and serves as a proxy for comorbidities 
and overall health in the patients undergoing surgery. American Society of Anesthesiologists 
grade of 3 or greater has previously been identified as a risk factor for SSI41, and this is 
reasonable given these patient’s increased burden of disease. We also found that being diagnosed 
to a skilled nursing facility versus being discharged home was an independent risk factor for 
infection. Two explanations for this finding are suboptimal postoperative wound care at the 
skilled nursing facility or increased inherent risk in patients being discharged to the skilled 
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nursing facility. The later is more likely the case. Patients that are discharged to the skilled 
nursing facility instead of an inpatient rehab or to their home likely have a greater burden of 
illness and more comorbidities than those patients not going to skilled nursing facilities. This 
would agree with our finding that ASA grade is associated with increased risk for SSI.  
Having a previous history of any SSI, orthopedic or otherwise, was associated with 
infection in the univariate analysis but not the adjusted analysis. According to a recent review by 
Pull ter Gunne et al, a prior history of SSI was associated with developing an SSI more often in 
the literature than not42. That this variable was not significantly associated with infection in our 
adjusted analysis (AOR 4.24; 95% CI, 0.718-19.145) is probably due to our study’s sample size. 
Even so, this variable’s association is an interesting finding because it is the only modifiable risk 
factor identified as significant in our study.  While we cannot modify that these patients have 
previously had a SSI, we can modify how we approach prophylaxis for these patients and further 
research needs to be undertaken to determine how to treat this population prophylactically.   
Intrawound vancomyin was the only other modifiable risk factor analyzed (AOR 0.479; 
95% CI 0.164-1.284) but was not significantly associated with a decreased risk in SSI in the 
adjusted model.  Although this study lacked sufficient power to detect a statistically significant 
difference in the total number of SSIs, we did find a statistically significant decrease in acute, 
deep Staphylococcus infections between our groups. There were seven such S. aureus or S. 
epidermidis infections (2.05%) in the Historical cohort compared to zero such infections in the 
Vanco cohort (p=0.008). This outcome was not analyzed with multiple logistic regression due to 
the small number of events.  
 Our results are similar to those published by Sweet et al last year, which is the most 
definitive work to date on the effectiveness of intrawound vancomycin powder use to prevent 
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SSIs in spine surgery. In their prospective cohort study, 911 of 1,732 consecutive posterior 
instrumented thoracic and lumbar spinal arthrodeses from 2000 to 2006 had 2 g of intrawound 
vancomycin powder added as prophylaxis25. They had a deep infection rate of 2.6% in the 821 
patients not receiving the vancomycin powder compared to 0.2% in the group receiving the 
vancomycin powder25. The reduction was statistically significant (p<0.0001). Similar to our 
study they found 71% of their infections in the non-vancomycin group to be Staphylococcus 
compared to no deep Staphylococcus infections in the vancomycin group25.  
 O’Neill et al published a study on the effectiveness of intrawound vancomycin powder to 
prevent infections following spinal surgery in a trauma population27. They compared 54 control 
patients not receiving the vancomycin powder to 56 patients receiving the powder over a two 
year period27. They found seven infections (13%) in the group not receiving vancomycin and no 
infections in the vancomycin group (p=0.02)27. Again these are similar findings to our study.  
 Finally, in a case series report, Molinari et al added 1 g of vancomycin powder to the 
operative site prior to closure in all of their spinal surgeries from 2005 to 201043. They report a 
0.99% rate of deep wound infections and suggested that their low rate of deep wound infections 
is associated with the use of vancomycin powder43. With the addition of our study to these 
previous three studies, adding vancomycin powder to the operative site is clearly associated with 
a reduced deep infection rate in instrumented spinal surgeries.  
The exact mechanism by which vancomycin prevents infection when used in this manner 
is not fully understood, however Sweet et al also gathered prospective serum and surgical drain 
fluid levels of vancomycin from their study patients up to post-op day three and found that 80% 
of their patients receiving intrawound vancomycin had serum levels less than 0.6 µg/ml post-op 
day one25.  Of the 20% of those patients that did have serum vancomycin levels greater than 0.6 
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µg/ml, the average level was 1.6 µg/ml and only 6% had detectable serum levels of vancomycin 
after post-op day one. However, the concentrations of vancomyin collected from the wound 
drain were 1,457 µg/ml on average on post-op day zero, and diminished over the next three days 
to an average of 128 µg/ml25. Sweet et al have shown that applying vancomycin powder to the 
surgical wound results in high doses of vancomycin in the surgical wound where prophylaxis is 
desired without appreciable systemic distribution of the antibiotic.  
 O’Neill et al have suggested the intrawound vancomycin powder is effective at 
preventing infection via a post-antibiotic effect (PAE)27. Gram-positive bacteria utilize a thick 
peptidoglycan (PG) cell wall as a main defense against hostile environments, including the 
human immune system. An integral part of the structure of the PG cell wall is the cross-linking 
of peptide chain subunits via transpeptidation. Vancomycin binds a precursor molecule in the 
extracellular space preventing PG synthesis and is bactericidal44. Vancomycin is concentration-
independent, however, the PAE of the drug is concentration-dependent45. After being exposed to 
high concentrations of the drug the bacteria are inhibited even after the removal of the drug45. 
This PAE may partly explain the drug’s effectiveness within the wound, as Sweet et al have 
shown concentrations extend well beyond the mean inhibitory concentration (MIC) for up to 
three days at least25. Delivering antibiotic locally is not a new concept in orthopedic surgery46,47, 
and is ideal because it decreases the systemic toxicities of IV drugs48; this is especially true with 
vancomycin, which is not readily absorbed. Further research is warranted to elucidate the exact 
mechanism by which vancomycin powder is preventing infection inside the wound. 
 Our study is limited in that it is retrospective and limited to data recorded in medical 
records. This study is dependent on the validity of that data. Although tobacco use is a possible 
risk factor for infection and other negative operative outcomes49 we were not able to reliably 
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assess tobacco use in this study. All of Dr. Burton’s elective procedures are required to be 
nicotine free before surgery, which accounts for the low smoking rates observed in this study. 
We were not able to assess the rate of smoking resumption following surgery; however, Dr. 
Burton has previously shown that up to 36% of his patients who have stopped smoking for 
surgery continue to cease smoking postoperatively at the one-year mark (personal 
communication, June 20, 2012). The strengths of this study are our relatively large sample size, 
consistency among operative characteristics between study groups, and the diversity of spinal 
procedures, diagnoses, and spinal levels included. All procedures are performed by a single 
surgeon, which limits variability within surgical technique. Although we did not use the CDC 
definitions for defining our infections, our definition required a positive tissue culture which is a 
less subjective definition.    
There are many facets of intrawound vancomycin powder use that need to be further 
elucidated. As previously stated, the exact antimicrobial mechanisms of this mode of local 
administration of vancomycin are unknown and warrant further research. The benefits of using 
intrawound vancomycin powder to treat current spinal SSIs needs to be studied. Exact dosing 
optimization studies need to be undertaken to determine the proper amount of vancomycin 
powder to use.  Finally, further research on how to best approach patients with a history of 
surgical site infections prior to spinal surgery is also necessary. This may be the only risk factor 
for SSI in our patient population that we can alter.  
Conclusion 
In conclusion, while we did not find a statistically significant decrease in total deep 
infections, as Sweet et al25 reported, we did find a statistically significant difference in deep 
Staphylococcus infections. Staphylococcus and S. aureus in particular are the most common 
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types of bacteria causing SSIs in posterior spinal surgery. The purpose of adding a gram positive 
covering antibiotic like vancyomycin to the prophylaxis regimen in posterior instrumented spinal 
arthrodeses would be to prevent Staphylococcus infection. This study shows that adding 
intrawound vancomycin powder to the prophylactic regimen accomplishes this.  
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Appendix Table A: Variable definitions and chart locations 
Variable Definition Location in Chart 
Age Age in years at date of 
surgery. Date of surgery- 
DOB 
Patient admission document 
Gender Male or Female Patient admission document 
Race Caucasian, African-
American, Hispanic, or other 
Patient admission document 
Body mass index Calculated from height in 
inches and weight in pounds 
Height and weight found in pre-
anesthesia testing document, ortho 
H&P or hospital admission patient 
profile 
Insurance type Categorized as Private, 
Medicare, Medicaid, or 
Workmen’s compensation. 
Private includes commercial 
HMO and PPO  
Patient admission document or 
hospital admission patient profile 
American Society of 
Anesthesiologists grade 
Grade recorded as 1,2,3, 4, or 
5 
Pre-anesthesia testing document, 
anesthesia OR form, or nursing 
OR flowsheet 
History of surgical site 
infection 
Yes or No Pre-anesthesia testing document or 
ortho H&P 
Current cigarrette use Yes or No Pre-anesthesia testing and ortho 
H&P 
Number of smoking 
pack years 
Number of packs per day 
multiplied by the number of 
years smoked 
Ortho H&P, or pre-anesthesia 
testing document 
Smoking quit date Date quit smoking Ortho H&P, pre-anesthesia testing 
or hospital admission patient 
profile 
Alcohol use Yes or No. Yes for any 
alcohol use. 
Pre-anesthesia testing, ortho H&P 
Illicit drug use Yes or No. Yes for any illicit 
drugs including marijuana 
Pre-anesthesia testing, ortho H&P 
Previous spinal 
surgeries 
Yes or No. Yes if surgery is 
in the same spinal area as 
current surgery. 
Ortho H&P, pre-anesthesia testing 
document. 
Length of stay Date of discharge - date of 
surgery 
Discharge date taken from 
discharge summary document 
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Discharge location Home, Inpatient Rehab, 
Skilled nursing facility, 
inpatient psych 
Discharge summary document 
Number of days of 
follow-up 
Date of most recent follow-
up in clinic with Dr. Burton – 
Date of surgery 
Dr. Burton’s clinic notes. 
Diagnosis Up to 3 diagnoses listed on 
the OR Operative report 
Dr. Burton’s OR operative report 
Blood transfusion Recorded as intraoperative if 
packed red blood cells were 
given during the operative 
time period, or post operative 
if given after the operative 
time period, or No if none 
given. 
PACU document, anesthesia 
record, and discharge summary 
document 
Number of residents The number of ortho 
residents assisting 
OR operative report, OR nursing 
flowsheet 
Estimated blood loss Volume of blood lost in 
milliliters 
Anesthesia record, PACU 
document 
Length of surgery Incision time-closure time, 
documented in military time 
OR Nursing flowsheet 
Number of levels 
instrumented 
Number of levels receiving 
instrumentation (e.g. L5-S1 
is one level) 
OR operative report 
Number of levels fused Number of levels being fused 
(e.g. L5-S1 is one level) 
OR operative report 
Associated anterior 
approach 
Recorded as Same-Day-
Front-Back, Same-Day-
Back-Front, Staged-Front-
Back, or Staged-Back-Front, 
depending on when the 
anterior approach was 
performed. Anterior 
approached occurring within 
90 days of the posterior 
approaches were considered 
associated 
OR operative reports, discharge 
summary documents, and Ortho 
clinic notes 
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Decompression Yes or No. Yes if 
laminectomy, 
laminoforaminotomy, 
foraminotomy, or any 
osteotomy 
OR operative report 
Pelvic fixation Yes or No. Yes if 
instrumentation was applied 
to the pelvis 
OR operative report 
Operative levels Categorized as Cervical, 
Thoracic, Thoracolumbar, or 
Lumbar 
OR operative report 
Hemovac drain use Yes or No. Yes if any 
surgical drain was placed 
OR operative report, OR nursing 
flowsheet 
Hair removal method Clippers, Razor, or none OR nursing flowsheet 
Preoperative Antibiotic 
given 
Quantity and type of 
antibiotic given IV (e.g. 
1GANCEF is one gram of 
ancef) 
Anesthesia record, PACU 
document 
Time of first dose of 
prophylactic antibiotic 
Time first dose was 
delivered, recorded in 
military time 
Anesthesia record, OR nursing 
flowsheet, PACU document 
Co-morbidities Up to 10 comorbidities were 
recorded. This variable is the 
sum number of those 
Ortho H&P and the pre-anesthesia 
testing document 
Hypertension Yes if patient had 
hypertension listed a 
comorbidity, else No 
Variable was recoded from Co-
morbidities 
Cardiac disease Yes if arrhythmia, atrial 
fibrillation, coronary artery 
disease, congestive heart 
failure or myocardial 
infarction history were listed 
in comorbidities, else No 
Variable was recoded from Co-
morbidities 
Diabetes mellitus Yes if insulin dependent 
diabetes mellitus, non-insulin 
dependent diabetes mellitus 
or diet controlled diabetes 
mellitus were listed as 
comorbidities, else No 
Variable was recoded from Co-
morbidities 
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Cerebral Palsy Yes if cerebral palsy listed in 
comorbidities, else No 
Variable was recoded from Co-
morbidities 
Respiratory Disease Yes if asthma, COPD, 
emphysema, chronic 
bronchitis, or other lung 
disease were listed in 
comorbidities, else No 
Variable was recoded from Co-
morbidities 
Renal disease Yes if history of kidney 
stones or renal insufficiency 
listed in comorbidities, else 
No 
Variable was recoded from Co-
morbidities 
Cancer Yes if history of any cancer 
listed in comorbidities 
(prostate, breast, GI, renal, 
etc.), else No 
Variable was recoded from Co-
morbidities 
Psychiatric Disease Yes if depression, anxiety, 
bi-polar disorder listed in 
comorbidities, else No 
Variable was recoded from Co-
morbidities 
Surgical Complications Complication associated with 
surgical hospital stay (e.g. 
UTI, pneumonia, dural tear, 
vertebroplasty, wound 
dehiscence, hematoma, etc.) 
Discharge summary, consultation 
reports 
Intrawound 
Vancomycin 
Yes or No OR operative report, OR nursing 
flowsheet 
Surgical site infection Yes or No. Yes if required 
operation and had a positive 
tissue culture, within 90 days 
of index surgery 
OR operative reports, 
microbiology lab report, infectious 
disease consultation reports 
Infection depth Deep or Superficial. Deep if 
deep tissue culture was 
positive 
OR operative reports, 
microbiology lab report, infectious 
disease consultation reports 
Staphylococcus Yes if deep or superficial 
culture was positive for 
Staphylococcus aureus or 
coagulase negative 
staphylococcus, else No 
Microbiology lab reports 
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Deep Staphylococcus Yes if deep culture was 
positive for Staphylococcus 
aureus or coagulase negative 
staphylococcus, else No 
Microbiology lab reports 
Staphylococcus aureus Yes if deep or superficial 
culture positive for MSSA or 
MRSA, else No 
Microbiology lab reports 
Deep Staphylococcus 
aureus 
Yes if deep culture positive 
for MSSA or MRSA 
Microbiology lab reports 
Superficial mixed 
culture 
Yes if superficial infection 
contained more than one 
bacteria, else No 
Microbiology lab reports 
Deep mixed culture Yes if deep infection 
contained more than one 
bacteria, else No 
Microbiology lab reports 
E. coli Yes of deep or superficial 
infection was positive for E. 
coli, else No 
Microbiology lab reports 
Other deep Yes if deep infection was  
something other than Staph 
or E.coli 
Microbiology lab reports 
Other superficial Yes if superficial infection 
was something other than 
Staph or E.coli 
Microbiology lab reports 
Number of days post op 
for infection 
Date of operation for 
infection – date of index 
surgery 
OR operative reports 
Number of operations 
for infection 
Number of operations patient 
had to treat the surgical site 
infection 
OR operative reports 
Number of hospital 
days for infection 
treatment 
Sum of days hospitalized for 
infection treatment 
Discharge summary, 
Infection occurred 
during index 
hospitalization 
Yes if surgical site infection 
diagnosed during index 
surgery hospital stay, else No 
Discharge summary 
Number of readmissions 
for infection treatment 
Number of time the patient 
was hospitalized for infection 
treatment 
Discharge summary, infectious 
disease consultation reports, OR 
operative report 
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IV antibiotics used to 
treat surgical site 
infection 
Yes or No Discharge summary, infectious 
disease consultation report 
Intrawound vancomycin 
used for surgical site 
infection treatment 
Yes or No OR operative reports, OR nursing 
flowsheet 
Wound vac use for 
infection treatment 
Yes or No Operative report, discharge 
summary, infectious disease 
summary 
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